A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies

Boldt, 1988, Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans, Cancer Res., 48, 4409 Grimm, 1982, Lymphokine activated killer cell phenomenon, 155, 1823 Lindemann, A., Hermann, F., Oster, W. & Mertelsmann, R., Blut, (In press) Lymphokine activated killer cells. Lotze, 1980, The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors, J. Immunol., 125, 1487, 10.4049/jimmunol.125.4.1487 Mertelsmann, 1986, Human interleukin 2: molecular biology, physiology and clinical possibilities, Immunobiology, 172, 400, 10.1016/S0171-2985(86)80121-8 Mitchell, 1988, Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma, J. Clin. Oncol., 6, 409, 10.1200/JCO.1988.6.3.409 North, 1982, Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor induced suppressor T cells, J. Exp. Med., 55, 1063, 10.1084/jem.155.4.1063 Ozer, 1982, In vitro-effects of 4-hydroxy-peroxycyclophosphamide on human immunoregulatory T subset function, J. Exp. Med., 155, 276, 10.1084/jem.155.1.276 Phillips, 1987, In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin2 and LAK cell therapy, J. Clin. Oncol., 5, 1933, 10.1200/JCO.1987.5.12.1933 Rayner, 1987, Lymphokine-activated killer (LAK) cells, 55, 1327 Rosenberg, 1988, Cancer therapy with interleukin-2: immunologic manipulations can mediate regression of cancer in humans, J. Clin. Oncol., 6, 403, 10.1200/JCO.1988.6.3.403 Rosenberg, 1987, A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, N. Engl. J. Med., 316, 889, 10.1056/NEJM198704093161501 Silagi, 1986, Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide, J. Biol. Response Mod., 5, 411 Taniguchi, 1983, Structure and expression of a cloned cDNA for human interleukin-2, Nature, Lond., 302, 305, 10.1038/302305a0 Thompson, 1988, Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation, J. Clin. Oncol., 6, 669, 10.1200/JCO.1988.6.4.669 Topalian, 1988, Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study, J. Clin. Oncol., 6, 839, 10.1200/JCO.1988.6.5.839 West, 1987, Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of cancer, N. Engl. J. Med., 316, 898, 10.1056/NEJM198704093161502